CATEGORY: METABOLIC & BLOOD SUGAR
One number from this diabetes trial is zero: nobody on the experimental drug had a single episode of severe low blood sugar. The drug, retatrutide, a weekly injection acting on three hormone receptors at once, lowered HbA1c, the standard three-month blood sugar gauge, by up to 1.9 percentage points over 40 weeks, versus 0.8 on placebo, in 537 adults with early type 2 diabetes.1 More than four of every five participants taking it finished below the 7% mark that treatment guidelines aim for. Weight fell too: up to 15.3% at the top dose, against 2.6% on placebo.
Three Receptors, One Weekly Shot
Semaglutide speaks to one hormone receptor, GLP-1. Tirzepatide speaks to two. Retatrutide adds a third, glucagon, whose job includes raising the body’s energy burn. Together the signals blunt appetite, help the pancreas release insulin when meals raise blood sugar, and step up energy use. Because they act mainly while sugar is high, drugs of this family rarely drive it dangerously low on their own, and in this trial severe lows simply never happened.
Who Took It, and What Changed
The 537 participants, seen at 48 sites in the United States, Mexico and India, had been diagnosed an average of two and a half years earlier and weren’t yet on any diabetes medication. A random draw placed each person on a low, middle or high weekly dose or on placebo, with the assignment hidden from patient and doctor alike.1 After 40 weeks, HbA1c had fallen between 1.7 and 1.9 points across the three doses, from a starting average of 7.9%. Weight was still dropping when the trial ended, with no sign of a plateau. The costs were the class’s usual ones. Nausea, diarrhea and vomiting showed up mostly during dose increases, an odd tingling or crawling skin sensation affected up to 4.5% of participants, and about 5% on the highest dose quit over side effects.
A Class Ahead of the Pharmacy
Retatrutide isn’t approved anywhere yet. This trial, its first completed phase 3 test in type 2 diabetes, is part of a wider program studying the same molecule for obesity, sleep apnea and knee arthritis. Keep the population in mind before mapping these numbers onto every diabetes patient: these were adults early in the disease, taking nothing else for it. Longer trials will have to show whether the control lasts and whether it becomes fewer heart attacks, kidney failures and deaths. Those studies are under way.
Key Takeaways
- Retatrutide lowered HbA1c by up to 1.9 points versus 0.8 on placebo over 40 weeks, and more than four in five participants ended below the 7% target; weight fell by as much as 15.3%.
- Severe low blood sugar never occurred. The common side effects were stomach-related, plus an unusual skin-tingling sensation in a small share of participants.
- The trial enrolled adults with early, untreated type 2 diabetes, and the drug has no approval yet, so this is a preview of a possible future option rather than something available today.
References
- Rosenstock J, Frias JP, et al. Efficacy and Safety of Retatrutide, a GIP, GLP-1, and Glucagon Receptor Agonist, in People with Type 2 Diabetes and Inadequate Glycaemic Control with Diet and Exercise (TRANSCEND-T2D-1): A Double-Blind, Randomised, Phase 3 Trial. The Lancet. 2026;S0140-6736(26)00967-0. link